At present, the GLP-1 receptor agonists that have been listed in China mainly include exenatide, liraglutide, exenatide long-acting preparations, dulaglutide, lisenatide, benraglutide, and polyethylene glycol losenatide. According to the duration of action, it can be divided into short-term and long-term GLP-1 receptor agonists. Short acting GLP-1 receptor agonists require multiple subcutaneous injections per day, while long acting GLP-1 receptor agonists can be injected subcutaneously once a day or once a week. When the human glucose concentration increases, GLP-1 receptor agonists can stimulate insulin secretion. When glucose concentration decreases and approaches normal, insulin secretion decreases. Therefore, GLP-1 receptor agonists stimulate insulin secretion in a glucose dependent manner. Meanwhile, GLP-1 receptor agonists reduce glucagon secretion in a glucose dependent manner. In addition, GLP-1 receptor agonists exert hypoglycemic effects through various mechanisms such as slowing gastric emptying, central appetite inhibition, and reducing food intake.